David Luo Senior Vice President, Clinical Operations | David has over 20 years of early and late phase drug development experience across multiple therapeutic areas, with a particular emphasis in immunotherapies and oncology.  David has made key clinical contributions to eight drug and drug device programs that resulted in regulatory approval by the FDA and other agencies. Most recently, David was Senior Vice President of Clinical Operations at Medikine, where he was responsible for clinical development and operations of its lead immuno-oncology biologic, an IL-7 mimetic. Prior to this, he served as VP of Clinical Operations for Erasca, where he led operational oversight of multiple clinical stage precision oncology programs; Synthorx, where he led clinical development and operations of its recombinant human non-alpha IL-2 biologic up until its acquisition by Sanofi; and Ignyta, where he oversaw multiple clinical stage precision oncology programs up until its acquisition by Roche, including its lead targeted therapy, Rozlytrek™, which was approved by regulatory agencies in the US, EU, and Japan.  Prior to Ignyta, David held multiple leadership positions within clinical operations at pharmaceutical and biotech companies, including Elevation Pharmaceuticals (acquired by Sunovion Pharmaceuticals) and Meritage Pharma (acquired by Shire), both of which subsequently achieved FDA approval in respiratory and inflammatory indications. 

David earned a Master of Public Health degree (with an emphasis in Toxicology and Environmental Health Sciences) from UCLA and a B.S. in Biology from UCSD.